D.E. Shaw & Co
HRTX icon

D.E. Shaw & Co’s Heron Therapeutics HRTX Stock Holding History

D.E. Shaw & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Sell
2,600,990
-403,650
-13% -$468K ﹤0.01% 2883
2025
Q4 		$3.91M Sell
3,004,640
-83,852
-3% -$104K ﹤0.01% 2511
2025
Q3 		$3.89M Sell
3,088,492
-111,807
-3% -$177K ﹤0.01% 2439
2025
Q2 		$6.62M Buy
3,200,299
+214,102
+7% +$437K 0.01% 1808
2025
Q1 		$6.57M Sell
2,986,197
-737,509
-20% -$1.43M 0.01% 1699
2024
Q4 		$5.7M Sell
3,723,706
-660,971
-15% -$1.07M 0.01% 1865
2024
Q3 		$8.73M Buy
4,384,677
+521,302
+13% +$1.24M 0.01% 1512
2024
Q2 		$13.5M Buy
3,863,375
+1,168,329
+43% +$3.59M 0.02% 1143
2024
Q1 		$7.47M Buy
2,695,046
+1,404,049
+109% +$3.53M 0.01% 1587
2023
Q4 		$2.19M Buy
1,290,997
+1,045,724
+426% +$1.15M ﹤0.01% 2596
2023
Q3 		$253K Sell
245,273
-103,687
-30% -$148K ﹤0.01% 3691
2023
Q2 		$405K Sell
348,960
-372,122
-52% -$664K ﹤0.01% 3502
2023
Q1 		$1.09M Sell
721,082
-65,998
-8% -$165K ﹤0.01% 3098
2022
Q4 		$1.97M Sell
787,080
-112,491
-13% -$362K ﹤0.01% 2953
2022
Q3 		$3.8M Sell
899,571
-715,411
-44% -$2.8M 0.01% 2387
2022
Q2 		$4.51M Sell
1,614,982
-419,247
-21% -$1.68M 0.01% 2248
2022
Q1 		$11.6M Buy
2,034,229
+683,738
+51% +$5M 0.02% 1468
2021
Q4 		$12.3M Sell
1,350,491
-81,438
-6% -$831K 0.02% 1473
2021
Q3 		$15.3M Sell
1,431,929
-532,221
-27% -$6.48M 0.02% 1196
2021
Q2 		$30.5M Sell
1,964,150
-243,240
-11% -$3.87M 0.04% 791
2021
Q1 		$35.8M Sell
2,207,390
-53,888
-2% -$961K 0.04% 639
2020
Q4 		$47.9M Buy
2,261,278
+168,612
+8% +$2.93M 0.06% 511
2020
Q3 		$31M Sell
2,092,666
-25,776
-1% -$402K 0.04% 608
2020
Q2 		$31.2M Sell
2,118,442
-206,661
-9% -$3.4M 0.05% 555
2020
Q1 		$27.3M Sell
2,325,103
-519,946
-18% -$9.77M 0.05% 480
2019
Q4 		$66.9M Buy
2,845,049
+1,207,750
+74% +$26.7M 0.1% 307
2019
Q3 		$30.3M Buy
1,637,299
+265,008
+19% +$4.88M 0.05% 590
2019
Q2 		$25.5M Sell
1,372,291
-99,305
-7% -$1.98M 0.04% 635
2019
Q1 		$36M Buy
1,471,596
+417,588
+40% +$10.9M 0.06% 478
2018
Q4 		$27.3M Buy
1,054,008
+473,127
+81% +$13M 0.05% 570
2018
Q3 		$18.4M Buy
580,881
+142,648
+33% +$5.31M 0.03% 815
2018
Q2 		$17M Sell
438,233
-537,780
-55% -$17.1M 0.03% 806
2018
Q1 		$26.9M Buy
976,013
+480,381
+97% +$10.9M 0.05% 541
2017
Q4 		$8.97M Buy
495,632
+255,457
+106% +$4.17M 0.02% 1098
2017
Q3 		$3.88M Buy
240,175
+182,875
+319% +$2.87M 0.01% 1565
2017
Q2 		$794K Buy
57,300
+28,048
+96% +$406K ﹤0.01% 2552
2017
Q1 		$439K Buy
29,252
+15,132
+107% +$209K ﹤0.01% 2788
2016
Q4 		$185K Buy
+14,120
New +$222K ﹤0.01% 3279
2016
Q3 		– Sell
-57,850
Closed -$1.04M – 3448
2016
Q2 		$1.04M Buy
57,850
+8,180
+16% +$160K ﹤0.01% 2386
2016
Q1 		$943K Buy
+49,670
New +$980K ﹤0.01% 2395
2015
Q4 		– Sell
-60,281
Closed -$1.47M – 3893
2015
Q3 		$1.47M Sell
60,281
-168,657
-74% -$5.62M ﹤0.01% 2319
2015
Q2 		$7.13M Buy
228,938
+216,205
+1,698% +$4.07M 0.01% 1226
2015
Q1 		$185K Sell
12,733
-6,877
-35% -$77.5K ﹤0.01% 3462
2014
Q4 		$197K Buy
+19,610
New +$160K ﹤0.01% 3810

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.29B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return